ID

11850

Descripción

Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology; ODM derived from: https://clinicaltrials.gov/show/NCT02140736

Link

https://clinicaltrials.gov/show/NCT02140736

Palabras clave

Versiones (1)
  1. 10/8/15 10/8/15 - Julian Varghese
Subido en

10 de agosto de 2015

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Chemotherapy-induced Symptomatic Anemia NCT02140736

Inglés

Eligibility Chemotherapy-induced Symptomatic Anemia NCT02140736

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

patients of more than 18 years of age
Descripción

patients of more than 18 years of age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
patients presenting with anemia following chemotherapy
Descripción

patients presenting with anemia following chemotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3665472
UMLS CUI [2]
C0002871
patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy
Descripción

patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0280100
UMLS CUI [2]
C3665472
UMLS CUI [3]
C0376545
- the patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle)
Descripción

- the patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle)

Tipo de datos

boolean

patients eligible for epoetin alfa biosimilar treatment
Descripción

patients eligible for epoetin alfa biosimilar treatment

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013893
UMLS CUI [1,2]
C0357126
Exclusion Criteria
Descripción

Exclusion Criteria

patients are not receiving chemotherapy
Descripción

patients are not receiving chemotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3665472
patients already included in an epoetin zeta trial
Descripción

patients already included in an epoetin zeta trial

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2242969
UMLS CUI [1,2]
C1997870
patients presenting with a contraindication to epoetin zeta
Descripción

patients presenting with a contraindication to epoetin zeta

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0522473
UMLS CUI [1,2]
C1997870
patients presenting with hypersensitivity to the active principle or any of the excipients
Descripción

patients presenting with hypersensitivity to the active principle or any of the excipients

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0014822
patient with erythroblastopenia or acquired pure red cell aplasia (aprca)
Descripción

patient with erythroblastopenia or acquired pure red cell aplasia (aprca)

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0877221
UMLS CUI [2]
C0340961
patient with uncontrollable arterial hypertension
Descripción

patient with uncontrollable arterial hypertension

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1868885
patients who cannot receive adequate prophylaxis by antithrombotic agents
Descripción

patients who cannot receive adequate prophylaxis by antithrombotic agents

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0522473
UMLS CUI [1,2]
C1704311
Volver a la parte superior de la página

Similar models

Eligibility Chemotherapy-induced Symptomatic Anemia NCT02140736

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
age
Item
patients of more than 18 years of age
boolean
C0001779 (UMLS CUI [1])
Chemotherapy | Anemia | Hematologic Neoplasms
Item
patients presenting with anemia following chemotherapy
boolean
C3665472 (UMLS CUI [1])
C0002871 (UMLS CUI [2])
Solid tumour | Chemotherapy | Hematologic Neoplasms
Item
patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy
boolean
C0280100 (UMLS CUI [1])
C3665472 (UMLS CUI [2])
C0376545 (UMLS CUI [3])
patient inclusion regardless of chemotherapy
Item
- the patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle)
boolean
Eligibility Determination; Epoetin Alfa
Item
patients eligible for epoetin alfa biosimilar treatment
boolean
C0013893 (UMLS CUI [1,1])
C0357126 (UMLS CUI [1,2])
Chemotherapy
Item
patients are not receiving chemotherapy
boolean
C3665472 (UMLS CUI [1])
clinical trial participant (history); epoetin zeta
Item
patients already included in an epoetin zeta trial
boolean
C2242969 (UMLS CUI [1,1])
C1997870 (UMLS CUI [1,2])
Contraindication; epoetin zeta
Item
patients presenting with a contraindication to epoetin zeta
boolean
C0522473 (UMLS CUI [1,1])
C1997870 (UMLS CUI [1,2])
Hypersensitivity; Erythropoietin
Item
patients presenting with hypersensitivity to the active principle or any of the excipients
boolean
C0020517 (UMLS CUI [1,1])
C0014822 (UMLS CUI [1,2])
Decreased erythroid precursor production | Acquired red cell aplasia
Item
patient with erythroblastopenia or acquired pure red cell aplasia (aprca)
boolean
C0877221 (UMLS CUI [1])
C0340961 (UMLS CUI [2])
Uncontrolled hypertension
Item
patient with uncontrollable arterial hypertension
boolean
C1868885 (UMLS CUI [1])
Contraindication; Antithrombotic Agents
Item
patients who cannot receive adequate prophylaxis by antithrombotic agents
boolean
C0522473 (UMLS CUI [1,1])
C1704311 (UMLS CUI [1,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial